BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) Fundamental Analysis & Valuation

NASDAQ:BBOT • US1079241022

Current stock price

8.81 USD
+0.13 (+1.5%)
Last:

This BBOT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. BBOT Profitability Analysis

1.1 Basic Checks

  • BBOT had positive earnings in the past year.
  • BBOT had a negative operating cash flow in the past year.
BBOT Yearly Net Income VS EBIT VS OCF VS FCFBBOT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 2M 4M 6M

1.2 Ratios

  • BBOT has a better Return On Assets (2.39%) than 88.63% of its industry peers.
  • Looking at the Return On Equity, with a value of 2.49%, BBOT belongs to the top of the industry, outperforming 89.60% of the companies in the same industry.
Industry RankSector Rank
ROA 2.39%
ROE 2.49%
ROIC N/A
ROA(3y)-3.68%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BBOT Yearly ROA, ROE, ROICBBOT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 200 -200 -400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for BBOT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BBOT Yearly Profit, Operating, Gross MarginsBBOT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. BBOT Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, BBOT has more shares outstanding
  • BBOT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BBOT Yearly Shares OutstandingBBOT Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M 15M 20M
BBOT Yearly Total Debt VS Total AssetsBBOT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • An Altman-Z score of 51.02 indicates that BBOT is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 51.02, BBOT belongs to the top of the industry, outperforming 95.76% of the companies in the same industry.
  • BBOT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 51.02
ROIC/WACCN/A
WACCN/A
BBOT Yearly LT Debt VS Equity VS FCFBBOT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 0.33 indicates that BBOT may have some problems paying its short term obligations.
  • With a Current ratio value of 0.33, BBOT is not doing good in the industry: 91.52% of the companies in the same industry are doing better.
  • BBOT has a Quick Ratio of 0.33. This is a bad value and indicates that BBOT is not financially healthy enough and could expect problems in meeting its short term obligations.
  • BBOT has a worse Quick ratio (0.33) than 91.14% of its industry peers.
Industry RankSector Rank
Current Ratio 0.33
Quick Ratio 0.33
BBOT Yearly Current Assets VS Current LiabilitesBBOT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 500K 1M 1.5M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. BBOT Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 17.40% over the past year.
EPS 1Y (TTM)17.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-58.45%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to decrease by -111.94% on average over the next years. This is quite bad
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-1034.53%
EPS Next 2Y-192.84%
EPS Next 3Y-111.94%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BBOT Yearly EPS VS EstimatesBBOT Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

1

4. BBOT Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 44.05, the valuation of BBOT can be described as expensive.
  • Based on the Price/Earnings ratio, BBOT is valued cheaply inside the industry as 90.56% of the companies are valued more expensively.
  • BBOT's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 25.23.
  • BBOT is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 44.05
Fwd PE N/A
BBOT Price Earnings VS Forward Price EarningsBBOT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BBOT Per share dataBBOT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

  • BBOT's earnings are expected to decrease with -111.94% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-192.84%
EPS Next 3Y-111.94%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BBOT Dividend Analysis

5.1 Amount

  • No dividends for BBOT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BBOT Fundamentals: All Metrics, Ratios and Statistics

BRIDGEBIO ONCOLOGY THERAPEUT

NASDAQ:BBOT (3/23/2026, 1:31:24 PM)

8.81

+0.13 (+1.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-05
Earnings (Next)05-07
Inst Owners69.87%
Inst Owner Change2.8%
Ins Owners0.11%
Ins Owner Change6.09%
Market Cap705.06M
Revenue(TTM)N/A
Net Income(TTM)4.72M
Analysts86.67
Price Target24.48 (177.87%)
Short Float %3.99%
Short Ratio7.56
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.59%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)4.3%
EPS NY rev (3m)3.09%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 44.05
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.73
P/tB 3.73
EV/EBITDA N/A
EPS(TTM)0.2
EY2.27%
EPS(NY)-2.35
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0
BVpS2.36
TBVpS2.36
PEG (NY)N/A
PEG (5Y)N/A
Graham Number3.26
Profitability
Industry RankSector Rank
ROA 2.39%
ROE 2.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-3.68%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.33
Quick Ratio 0.33
Altman-Z 51.02
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-58.45%
EPS Next Y-1034.53%
EPS Next 2Y-192.84%
EPS Next 3Y-111.94%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-1399.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-23218.2%
EBIT Next 3Y-650.8%
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

BRIDGEBIO ONCOLOGY THERAPEUT / BBOT Fundamental Analysis FAQ

What is the fundamental rating for BBOT stock?

ChartMill assigns a fundamental rating of 2 / 10 to BBOT.


What is the valuation status of BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) stock?

ChartMill assigns a valuation rating of 1 / 10 to BRIDGEBIO ONCOLOGY THERAPEUT (BBOT). This can be considered as Overvalued.


How profitable is BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) stock?

BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) has a profitability rating of 2 / 10.


What are the PE and PB ratios of BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) stock?

The Price/Earnings (PE) ratio for BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) is 44.05 and the Price/Book (PB) ratio is 3.73.


How financially healthy is BRIDGEBIO ONCOLOGY THERAPEUT?

The financial health rating of BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) is 5 / 10.